Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of June 2017. The filing serves to incorporate by reference a press release dated June 20, 2017 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. The filing notes that the information is incorporated into various Registration Statements on Forms F-3 and S-8.
Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.
Material Changes
The filing text does not disclose specific material changes in financial position or operations. It references a press release issued on June 20, 2017, but the content of that release is not included in the provided text, preventing an analysis of changes versus prior periods.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. The document explicitly incorporates a press release by reference but does not reproduce its content, except for a specific quote by Onno van de Stolpe which is excluded from the incorporation by reference.
Key Facts for Investor Verification
- Company Identity: The filing is for Galapagos NV, not Lakefront Biotherapeutics NV (as indicated in the request metadata).
- Document Purpose: This is a procedural filing to incorporate a press release dated June 20, 2017, into the company's registration statements.
- Data Availability: The provided text contains no financial figures; investors must review the attached Exhibit 99.1 (the press release) for substantive information.
- Reporting Status: The company files annual reports under Form 20-F.